The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
Open accessAbstract
Overexpression of proinflammatory, type 1 cytokines has been demonstrated in psoriasis and is believed to be of pathophysiological importance. IL-10 is a type 2 cytokine with major impact on immunoregulation, since it inhibits type 1/proinflammatory cytokine formation. Therefore, we investigated its role in psoriasis. We found a relative deficiency in cutaneous IL-10 mRNA expression compared with other inflammatory dermatoses. Interestingly, patients during established antipsoriatic therapy showed higher IL-10 mRNA expression of peripheral blood mononuclear cells than patients before therapy. This suggested that IL-10 may have antipsoriatic capacity. Therefore, we performed a phase 2 pilot trial with subcutaneous IL-10 administration (8 microg/kg/d) over 24 d in three patients. Clinical efficiency measured by objective and subjective parameters was found. Immunosuppressive effects (depressed monocytic HLA-DR expression, TNF-alpha and IL-12 secretion capacity, IL-12 plasma levels, and responsiveness to recall antigens) as well as a shift toward a type 2 cytokine pattern (increasing proportion of IL-4, IL-5, and IL-10 producing T cells, selective increase in IgE serum levels) were observed. Remarkably, IL-10 administration also enhanced the intracutaneous IL-10 mRNA expression. Our investigations demonstrate the major importance of IL-10 in psoriasis and show that IL-10 administration represents a new therapeutic approach. This is the first report on IL-10 therapy for cutaneous disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Wegmann, T. G., Lin, H., Guilbert, L., & Mosmann, T. R. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90235-d · Cited by 2,852
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., & Trinchieri, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1041 · Cited by 1,385
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Self-citationvan Deventer, S., Elson, C., & Fedorak, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9247454 · Cited by 486
Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
ETTEHADI, P., GREAVES, M. W., WALLACH, D., ADERKA, D., & CAMP, R. D. R. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06244.x · Cited by 481
T Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset
Schlaak, J. F., Buslau, M., Jochum, W., Hermann, E., Girndt, M., Gallati, H., Büschenfelde, K.-H. M. Z., & Fleischer, B. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371752 · Cited by 455
Uyemura, K., Yamamura, M., Fivenson, D. F., Modlin, R. L., & Nickoloff, B. J. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371679 · Cited by 450
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.09.002 · Cited by 977
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Self-citationEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Boniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
Immune surveillance in the skin: mechanisms and clinical consequences
Kupper, T. S., & Fuhlbrigge, R. C. (2004) · Nature Reviews Immunology · doi:10.1038/nri1310 · Cited by 805
Th2 Cytokines and Atopic Dermatitis
B. Brandt, E. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000110 · Cited by 655
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Lebwohl, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12954-6 · Cited by 548
Blumberg, H., Conklin, D., Xu, W., Grossmann, A., Brender, T., Carollo, S., Eagan, M., Foster, D., Haldeman, B. A., Hammond, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00187-8 · Cited by 547
Austin, L. M., Ozawa, M., Kikuchi, T., Walters, I. B., & Krueger, J. G. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00749.x · Cited by 485
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
“Proof of principle by IL-10 therapy: a new therapeutic approach.”
InfluentialMocellin, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00009-1 · Cited by 463
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., Jacyna, M., Lashner, B. A., Gangl, A., Rutgeerts, P., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.20196 · Cited by 458
Kamradt, T., & Mitchison, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440907 · Cited by 457
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes
Moreau, P., Adrian-Cabestre, F., Menier, C., Guiard, V., Gourand, L., Dausset, J., Carosella, E. D., & Paul, P. (1999) · International Immunology · doi:10.1093/intimm/11.5.803 · Cited by 411
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Williams, L., Bradley, L., Smith, A., & Foxwell, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.567 · Cited by 393
Immune modulation by curcumin: The role of interleukin-10
Mollazadeh, H., Cicero, A. F. G., Blesso, C. N., Pirro, M., Majeed, M., & Sahebkar, A. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1358139 · Cited by 381
Baliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
Scanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Saxena, A., Khosraviani, S., Noel, S., Mohan, D., Donner, T., & Hamad, A. R. A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.10.031 · Cited by 306
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028548 · Cited by 302
New insights into the molecular mechanism of interleukin-10-mediated immunosuppression
Grütz, G. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0904484 · Cited by 296
A role for T cell-derived interleukin 22 in psoriatic skin inflammation
Boniface, K., Guignouard, E., Pedretti, N., Garcia, M., Delwail, A., Bernard, F.-X., Nau, F., Guillet, G., Dagregorio, G., Yssel, H., et al. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03511.x · Cited by 290
Lew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Oxidative stress in the pathogenesis of psoriasis
Zhou, Q., Mrowietz, U., & Rostami-Yazdi, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.06.033 · Cited by 274
Molecular mechanisms of interleukin-10-mediated inhibition of NF-κ B activity: a role for p50
DRIESSLER, F., VENSTROM, K., SABAT, R., ASADULLAH, K., & SCHOTTELIUS, A. J. (2003) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02342.x · Cited by 269
Self-citationMechanism of HBD-3 deficiency in atopic dermatitis
Howell, M. D., Boguniewicz, M., Pastore, S., Novak, N., Bieber, T., Girolomoni, G., & Leung, D. Y. M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.08.008 · Cited by 208
Interleukin-10 Downregulates Anti-Microbial Peptide Expression in Atopic Dermatitis
Howell, M. D., Novak, N., Bieber, T., Pastore, S., Girolomoni, G., Boguniewicz, M., Streib, J., Wong, C., Gallo, R. L., & Leung, D. Y. M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23776.x · Cited by 193
Baccouri, O., Boukerb, A. M., Farhat, L. B., Zébré, A., Zimmermann, K., Domann, E., Cambronel, M., Barreau, M., Maillot, O., Rincé, I., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00881 · Cited by 117
“IL-10 has interesting impact on immunoregulation, since it inhibits type 1/proinflammatory cytokine formation (Asadullah et al., 1998).”
BackgroundGlowacka, E., Lewkowicz, P., Rotsztejn, H., & Zalewska, A. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0037-0 · Cited by 60
Metadata
- Authors
- Asadullah, K., Sterry, W., Stephanek, K., Jasulaitis, D., Leupold, M., Audring, H., Volk, H. D., & Döcke, W. D.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 783-794
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2089323062
- Cited by
- 415
- References
- 37
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.